MDNews - Mid Penn

Innovations 2022

Issue link: https://viewer.e-digitaledition.com/i/1481285

Contents of this Issue

Navigation

Page 5 of 15

This allows for the individualization of therapeutic management." Fol low i n g a PET- CT s c a n u si n g Locametz, nuclear medicine physicians can interpret the findings on the same day and share them with patients and their families during a consultation. If the Locametz results support proceeding with Pluvicto therapy, the nuclear medicine physician can approve that patient for Pluvicto therapy during the visit. If the patient wishes to proceed, their f irst treatment at Penn State Cancer Institute can be set up for the earliest available date. REDUCING THE BURDEN OF TREATMENT Administration of Pluvicto treatment is straightforward when done by a trained nuclear medicine technologist. Compared with the side effects of typical chemo- therapies used for advanced cancers, Pluvicto is generally well-tolerated by most patients. "When patients arrive for an infusion, we take vital signs and place two IV cath- eters, one in each arm," says Jessica Meley, chief nuclear medicine technologist in the Department of Radiology at Penn State Health. "We use one catheter to deliver Pluvicto and the other to administer hydrat- ing fluids and other medications. We infuse Pluvicto for five minutes and then take vital signs 30 minutes later. Patients are with us for about two hours from start to finish." Patients receive six such infusions, spaced six weeks apart, which makes it a convenient regimen for most patients. "The majority of patients experience little discomfort and few side effects," Dr. Tulchinsky says. "The side effect profile is relatively well tolerated. Not only is Pluvicto effective where other treatments have failed, but it's also much less burdensome and allows most patients to maintain their well-being through the treatment course." Meet the Physician: Mark Tulchinsky, MD, FACNM, FSNMMI + Professor of radiology and medicine, Penn State College of Medicine + Associate director of nuclear medicine, Penn State Health Milton S. Hershey Medical Center + Fellowship: Nuclear medicine, George Washington University School of Medicine, Washington, D.C. + Residency: Internal medicine, Georgetown University in Washington, D.C. + Medical school: First Tashkent State Medical Institute POTENTIAL FUTURE APPLICATIONS T wo pha se 3 tria ls a re investigating how Pluv icto cou ld possibly benef it more patients at ea rlier stages of pros- tate ca ncer. The PSM A fore tria l is studying the treatment 's potentia l effect on image- ba se d prog re s sion-f re e s u r v iv a l i n patients w it h mCR PC who have not received ta xa ne-based chemotherapy. The tria l is assessing whether Pluvicto therapy can be as effective as a change in a ndrogen receptor pathway inhibitor. 2 The PSM Addition tr ia l, for which Penn State Ca ncer Institute is recruit- ing pa r ticipa nts, is investigating the safety and efficacy of Pluvicto plus stan- dard of care compared with standard of ca re a lone in patients with metastatic hor mone -sen sit ive pros t at e ca ncer (m HSPC). 3 Un li ke mCR PC, patients w it h m H SPC a re i n a si g n i f ica nt ly ea rlier stage of ca ncer. Dr. Tulchinsky is excited about inves- tigating the potentia l of Pluvicto to treat prostate ca ncer at much ea rlier stages. He predicts t hat i n t he nex t decade, nuclear medicine physicians will be able to use thera nostics at a n even higher t e c h n ic a l le ve l t h a t s hou ld en a ble deter mining indiv idua lized dosa ges depending on the size, accumulation, a nd retention of the dr ug in the ca n- cer metastases. Currently, FDA approva l for Pluvicto requires g iving the sa me dosage to a ll patients. The predicted developments will a llow physicians to deliver Pluvicto a n d o t h e r r a d i o p h a r m a c e u t i c a l s w it h even g reater i ndiv idua li zation a nd e x p e c t e d ef fe c t ivene s s . I n t he mea ntime, Dr. Tulchinsky a nticipates eventua lly administering Pluvicto to up to six patients per week. "I hope other physicia ns will recog- nize Pluvicto as a pivota l therapy that not only has a relatively low burden of side effects a nd patient inconvenience but a l s o i mpr ove s l ive s de s pit e a n adva nced prostate ca ncer diag nosis," Dr. Tulchinsky says. "This is a sophisti- cated and effective treatment approach that hea lthcare providers at Penn State Hea lth are committed to ma king avail- able to as ma ny appropriately selected patients a s possible a nd a s prompt ly as possible." D r. T u l c h i n s k y c o m m e n d s t h e members of the Genitourina r y Tumor Board for their efforts to bring this novel therapy to Penn State Cancer Institute. " T h i s t e a m w or k c o u l d n o t h a v e succeeded without the strong suppor t of the Depa r tment of R adiolog y lead- ership, including the cha ir, Timothy Mosher, MD, a nd the chief of nuclea r medicine, Thomas Allen, MD," he said. ■ To learn more, visit cancer.psu.edu. References 1. Sartor O, de Bono J, Chi KN et al. Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385:1091-1103, doi:10.1056/NEJMoa2107322. 2. Sartor OA , Morris MJ, Chi KN et al. PSMAfore: A phase 3 study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2022;40(6). doi:10.1200/JCO.2022.40.6 _ suppl. TPS211. 3. Sartor OA , Tagawa ST, Saad F et al. PSMAddition: A phase 3 trial to compare treatment with 177Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-resistant prostate cancer. J Clin Oncol. 2022;40(6). doi:10.1200/JCO.2022.40.6 _ suppl. TPS210. 0 6 ❱❱❱❱❱ C O V E R F E A T U R E

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Mid Penn - Innovations 2022